Arterial inflammation in bronchial asthma

Journal of Nuclear Cardiology

Volumn 20, Issue 3, 2013, Pages 385-395

  Vijayakumar, Jayanthi ^a   Subramanian, Sharath ^a   Singh, Parmanand ^a   Corsini, Erin ^a   Fontanez, Sara ^a   Lawler, Meredith ^a   Kaplan, Rebecca ^a   Brady, Thomas J ^a   Hoffmann, Udo ^a   Tawakol, Ahmed ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

aorta; atherosclerosis; bronchial asthma; inflammation; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; STEROID;

ADULT; AORTA; ARTERY DISEASE; ARTERY INFLAMMATION; ARTICLE; ASTHMA; ATHEROSCLEROSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL;

ADULT; AGED; AORTA; ARTERITIS; ASTHMA; ATHEROSCLEROSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84878019876     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-013-9697-z     Document Type: Article

References (59)

1. World Health Organization. Fact Sheet No. 206. Bronchial Asthma. Revised January 2000.
2. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma; executive summary of the GINA dissemination committee report. Allergy 2004;58:469-78.
3. O'Sullivan SM. Asthma death, CD8+ T cells, and viruses. Proc Am Thorac Soc. 2005;2:162-5.
4. Iribarren C, Tolstykh IV, Eisner MD. Are patients with asthma at increased risk of coronary heart disease? Int J Epidemiol. 2004;33:743-8.
5. Schroeder EB, et al. Lung function and incident coronary heart disease: The atherosclerosis risk in communities study. Am J Epidemiol. 2003;158:1171-81.
6. Schanen JG, et al. Asthma and incident cardiovascular disease: The atherosclerosis risk in communities study. Thorax. 2005;60:633-8.
7. Onufrak S, Abramson J, Vaccarino V. Adult-onset asthma is associated with increased carotid atherosclerosis among women in the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2007;195:129-37.
8. Bjermer L. Asthma is a systemic inflammation - not a local disease. Broad anti-inflammatory treatment is necessary. Lakartidningen. 2009;106:1905-8.
9. Takemura M, et al. High sensitivity C-reactive protein in asthma. Eur Respir J. 2006;27:908-12.
10. Wu TL, et al. A panel of multiple markers associated with chronic systemic inflammation and the risk of atherogenesis is detectable in asthma and chronic obstructive pulmonary disease. J Clin Lab Anal. 2007;21:367-71.
11. Jousilahti P, et al. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease - baseline findings of the PAIS project. Atherosclerosis. 2001;156:451-6.
12. De Caterina R, Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med. 2004;350:4-7.
13. Qiu H, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA. 2006;103:8161-6.
14. Nobili E, et al. Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease. PLoS ONE. 2012;7:e41786.
15. Rudd JH, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-11.
16. Rudd JH, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871-8.
17. Rudd JH, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-6.
18. Tahara N, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-31.
19. Ishii H, et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: A randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin Ther. 2010;32:2337-47.
20. Fayad ZA, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet. 2011;378:1547-59.
21. Bural GG, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008;35:562-9.
22. Rudd JH, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009;2:107-15.
23. Kim TN, et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: Analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging. 2010;3:142-8.
24. Rogers IS, et al. Feasibility of FDG imaging of the coronary arteries: Comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010;3:388-97.
25. Rominger A, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611-20.
26. Paulmier B, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008;15:209-17.
27. Rudd JHF, et al. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-6.
28. Tawakol A, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-24.
29. Fitch K, et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: Relationship to metabolic syndrome and cardiac risk parameters. JAIDS. 2010;55:495-9.
30. Blaha MJ, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: Implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378:684-92.
31. Einstein AJ, et al. Agreement of visual estimation of coronary artery calcium from low-dose CT attenuation correction scans in hybrid PET/CT and SPECT/CT with standard Agatston score. J Am Coll Cardiol. 2010;56:1914-21.
32. Pedersen SF, et al. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010;31:423-9.
33. Graebe M, et al. Molecular pathology in vulnerable carotid plaques: Correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714-21.
34. Kubota R, et al. Intratumoral distribution of fluorine-18- fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-80.
35. Coulson JM, et al. Excessive aortic inflammation in chronic obstructive pulmonary disease: An 18F-FDG PET pilot study. J Nucl Med. 2010;51:1357-60.
36. Hancox RJ, et al. Systemic inflammation and lung function in young adults. Thorax. 2007;62:1064-8.
37. Knoflach M, et al. Allergic rhinitis, asthma, and atherosclerosis in the Bruneck and ARMY studies. Arch Intern Med. 2005;165:2521-6.
38. Qian FH, et al. High-sensitivity C-reactive protein: A predicative marker in severe asthma. Respirology. 2008;13:664-9.
39. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit. 2002;8:RA5-12.
40. Jenny NS, et al. In the elderly, interleukin-6 plasma levels and the -174G > C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002;22:2066-71.
41. Halasz A, et al. Role of TNF-alpha and its 55 and 75 kDa receptors in bronchial hyperreactivity. Respir Med. 2002;96:262-7.
42. Sumitomo M, et al. Serum levels of tumor necrosis factor alpha and soluble tumor necrosis factor-receptor I in asthmatic patients and patients with chronic respiratory tract infection. Arerugi. 1997;46:1136-47.
43. Goodman RB, et al. Cytokine-stimulated human mesothelial cells produce chemotactic activity for neutrophils including NAP-1/IL-8. J Immunol. 1992;148:457-65.
44. In KH, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 1997;99:1130-7.
45. Assimes TL, et al. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Hum Genet. 2008;123:399-408.
46. Dwyer JH, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004;350:29-37.
47. Cipollone F, et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665-70.
48. Helgadottir A, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-9.
49. Helgadottir A, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet. 2005;76:505-9.
50. Wouters EF, et al. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: Is there a connection? Proc Am Thorac Soc. 2009;6:638-47.
51. Persson C, et al. Peak expiratory flow and risk of cardiovascular disease and death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Am J Epidemiol. 1986;124:942-8.
52. Hozawa A, et al. Lung function and ischemic stroke incidence: The atherosclerosis risk in communities study. Chest. 2006;130:1642-9.
53. Weiler Z, et al. Pulmonary function correlates with arterial stiffness in asthmatic patients. Respir Med. 2010;104:197-203.
54. Schnabel E, et al. Association between lung function, hypertension and blood pressure medication. Respir Med. 2011;105:727-33.
55. Yiallouros PK, et al. Low serum high-density lipoprotein cholesterol in childhood is associated with adolescent asthma. Clin Exp Allergy. 2012;42:423-32.
56. Lee SJ, et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. 2008;49:1277-82.
57. Almuti K, et al. Effects of statins beyond lipid lowering: Potential for clinical benefits. Int J Cardiol. 2006;109:7-15.
58. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
59. Huang CC, et al. Statin use in patients with asthma: A nationwide population-based study. Eur J Clin Invest 2011;41:507-12.